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of child and adolescent mental disorders
Andrew James Lewis1*†, Megan Galbally2†, Tara Gannon1† and Christos Symeonides3†Abstract
This paper concerns future policy development and programs of research for the prevention of mental disorders
based on research emerging from fetal and early life programming. The current review offers an overview of
findings on pregnancy exposures such as maternal mental health, lifestyle factors, and potential teratogenic and
neurotoxic exposures on child outcomes. Outcomes of interest are common child and adolescent mental disorders
including hyperactive, behavioral and emotional disorders. This literature suggests that the preconception and
perinatal periods offer important opportunities for the prevention of deleterious fetal exposures. As such, the
perinatal period is a critical period where future mental health prevention efforts should be focused and prevention
models developed. Interventions grounded in evidence-based recommendations for the perinatal period could take
the form of public health, universal and more targeted interventions. If successful, such interventions are likely to
have lifelong effects on (mental) health.
Keywords: Child and adolescent mental health, Developmental origins (DOHaD), Fetal programming, Maternal
mental health, Obesity, Prevention, Teterogenic exposuresIntroduction
In recent years, a new understanding of the relationship
between the early environment and later psychiatric dis-
order has emerged as the new frontier of psychiatric re-
search. Such research has been largely inspired by the
developmental origins of health and disease (DOHaD)
model, which proposes a link between fetal development
and non-communicable diseases emerging in adulthood
such as cardiovascular disease and diabetes [1]. Applying
the DOHaD model to research focused on the etiology
of mental disorders has yielded some exciting findings.
However, translation of these findings to prevent the de-
velopment of mental disorders has yet to realize the full
potential promised by such discoveries. Fundamental to
this translational goal is the integration of prevention
science, and so this paper aims to provide a review on
what may be gained by linking this new understanding
of early development to efforts aimed at preventing
mental disorders in children and adolescents.* Correspondence: andrew.lewis@deakin.edu.au
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2014It is well established that the initial onset of high preva-
lence behavioral and emotional mental disorders frequently
commences in childhood or adolescence. Epidemiological
studies of population prevalence show rates of child and
adolescent mental health disorders to be consistently be-
tween 13% and 20% [2-4]. National surveys typically assess
common mental disorders in childhood and adolescence
across the categories of hyperactive, emotional and behav-
ioral disorders. National prevalence studies in Australia and
the US have found that attention deficit hyperactivity dis-
order (ADHD) is the most prevalent mental health disorder
among children and adolescents, followed by emotional
and behavioral problems [4,5].
Notably, prevalence rates for mental disorders increase
significantly as the child ages and also vary markedly
by gender. Gender differences become particularly pro-
nounced in relation to pubertal development. For in-
stance, prior to puberty boys are up to twice as likely
as girls to present with hyperactivity and behavioral prob-
lems, whereas over the pubertal transition girls become two
to three times more likely to present with depressive symp-
toms than boys [5-8]. The relationship between pubertal
development and mental health disorders suggests there
may be complex interactions between early developmentaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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later pubertal development. Gender differences in neurode-
velopmental pathways may be programmed early in life via
placental and fetal biology but this has attracted relatively
little attention as a source of possible gender differences in
mental disorders [9].
Early life programming
The fetal origins of adult disease model was originally
proposed by Barker to explain the observed associations
between undernutrition of the fetus, low birth weight
(defined as birth weight less than 2,500 grams) and an
increased risk of cardiovascular disease, diabetes and meta-
bolic syndrome in later life [10]. Low birth weight was ini-
tially considered to be the primary indicator of altered fetal
development within this model, although other measures of
fetal growth later emerged as equally relevant. With the
addition of other epidemiological findings such as the role
of preconception maternal body composition and under
nutrition, as well as the role of processes that do not impact
on fetal weight or growth, the model has been expanded to
include events beginning prior to conception as well as in
early postnatal life. To reflect the developmental aspects of
this model, it is now referred to as the DOHaD [11]. The
specific programming, in the form of epigenetic program-
ming, cell distribution, and establishment of endocrine sys-
tems and metabolic activity, is thought to vary according to
the timing, type, dosage and duration of various environ-
mental exposures across early development - now often re-
ferred to as the first 1,000 days of life [12].
The DOHaD model draws on a number of evolution-
ary concepts, the broadest of which is the notion of life
history. This idea suggests that the timing of develop-
ment is a target of genetic adaption such that, across
generations, species will adapt to produce the optimal
timing and duration for the development of their repro-
ductive life course [13]. The timing and duration of life
history traits such as birth, puberty, first reproduction,
gestation and onset of senescence, as well as rate of fetal
growth and number and size of offspring are all subject
to selection pressure [14]. However, within the individ-
ual’s life course, greater flexibility is required so each
member of a species displays some capacity for develop-
mental plasticity, adjusting the course and timing of de-
velopment to match prevailing environmental conditions
[15-17]. In theory, multiple phenotypes could be pro-
duced during development from a single genotype and
epigenetic mechanisms are thought to underpin such de-
velopmental plasticity [18]. For instance, DNA methyla-
tion discordance in epigenomic profiles across a number
of different tissues has been observed within monozy-
gotic twin pairs, although dizygotic pairs show an even
greater amount of discordance [19]. Developmental plas-
ticity suggests that the capacity to respond adaptively tofuture environmental conditions enhances the chances
of survival and reproductive fitness. This suggests that
development is a process where an organism is not only
responding to current environmental conditions, but it
is also using such information to predict future environ-
mental conditions. Earlier periods of development in the
fetal and early infancy period provide indications of the
most likely future conditions at a time when there is the
greatest degree of plasticity in development. So it follows
that the fetal period is regarded as a crucial determinate
of whether an organism sets its developmental pathway
according to expectations of adversity, stress and high
challenge, or develops with expectations of a more be-
nign environment [11].
Fetal programming, therefore, refers to the way in
which environmental events alter the course of fetal de-
velopment, resulting in enduring modifications in the
structure and function of biological systems. Program-
ming refers to the influence of a specific environmental
factor at a specific point in development, which creates
an enduring effect that may result in a bias towards a
certain response to subsequent environmental inputs at
a later point in development. The work of Meaney and
colleagues has been informed by the analogous concept
of hormonal imprinting, and they have mapped the role
of hormonal signals operating in pregnancy or early
postnatal interactions that are able to alter the sensitivity
of certain target tissues, often via altered expression of
hormone receptors, to these same hormones in later de-
velopment [20]. It should be noted, however, that the life
course of each species will be shaped to emphasize some
periods as more or less critical than others. The human
life course, for example, has been shaped by a trade-off
between bipedalism and gestational length such that the
neonatal and early infancy period is one of high vulner-
ability and plasticity. Furthermore, human puberty as
the immediate precursor to reproductive maturation is
another period of major biological programming.
These concepts developed within the DOHaD frame-
work can also be used to inform a novel model of vul-
nerability to mental disorder. Disease and disorder is
conceptualized in the DOHaD model in terms of a mis-
match between early programming and later environmen-
tal conditions. Depending on later environmental inputs,
what may have been ‘adaptive’ in the intrauterine environ-
ment may prove to be the basis of disease in a future post-
natal environment. Equally, the early programming of
behavior may prove to be a poor fit to later psychosocial
norms, educational expectations or interpersonal demands.
In the context of such a model, the psychiatric concept of
disorder should be considered not simply as a pathological
deviation from normality but as a mismatch across devel-
opment between early programming and later attempts to
adapt to prevailing environmental conditions [10]. Schlotz
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They noted that, in an ancestral environment, early devel-
opmental indicators that the environment was going to be
harsh or rapidly changing would encourage development of
a vigilant individual who is ready to respond quickly to new
stimuli and so be better adapted to an unpredictable envir-
onment [21]. In a modern context, when an individual
developing along this trajectory is placed in a modern
educational environment that demands long periods of
sustained attention and high levels of concentration, the
‘response ready’ phenotype would be maladaptive.
The DOHaD model is increasingly informed by the
emerging understanding of the epigenetic processes that
program fetal development. Epigenetic processes do not
alter the nucleotide sequence but are responsive to cues
from both genes and the environment. Epigenetic pro-
gramming of fetal and infant development is extremely
complex but it does appear that certain exposures can
alter epigenetic programming. The most frequently inves-
tigated epigenetic processes to date are DNA methylation
and histone modification, which play a fundamental role
in differentiation of cell structure and function during
embryogenesis [22]. Emerging evidence suggests that
epigenetic programming continues with significant
dynamism across the early postnatal period, with one
recent longitudinal study using a genome-wide study
of DNA suggesting that one-third of methylation sites
show dynamic methylation from birth to 18 months
[23] This has led to considerable interest in research
examining how altered epigenetic profiles might medi-
ate links between specific intrauterine and early postna-
tal exposures and future mental health outcomes [22].
The DOHaD model and child mental
health outcomes
An early application of the DOHaD model to mental health
outcomes was Barker et al.’s use of the Hertfordshire sam-
ple to examine rates of adult suicide as a function of birth
weight and growth in the first year. They found that birth
weight was not itself predictive but that the average weight
of 12-month-old infants was over 400 grams lower in cases
of suicide [24]. A significant body of research applying the
DOHaD model has now examined both birth weight and
more specific environmental exposures as predictors of
child and adolescent mental disorders [21,25,26].
Since dysregulation of the stress response is a common
feature of both emotional and behavioral disorders of
childhood and adolescence, mental health researchers
have focused much of their attention on factors within
fetal development that might impact on the postnatal
function of the stress response system. Links between
vulnerability to mental disorder and fetal programming
of metabolic functioning and immune response have
also been investigated but to a lesser extent. Specifically,there has been considerable focus on the early development
of the hypothalamic-pituitary-adrenal (HPA) system, which
is also linked to maturation of other systems responsible
for the regulation of circadian rhythms, physical growth
and the integration of limbic-cortical processes. As such,
the HPA system plays a critical part not only in stress regu-
lation but also in sleep, feeding, emotions and emotion-
regulation [27]. Animal models exposing pregnant mothers
to various types of stress or adversity show a clear impact
on the development of the offspring HPA system, that
manifests in emotional and behavioral disturbances such
as fearfulness, impulsivity and substance use. However, it
should be noted that the species-specific ontology of the
HPA system is important to consider when applying such
findings to humans, since exposures at different points in
fetal development may influence various systems involved
in neuroendocrine and autonomic responses to stressors
and the specific timing and degree of fetal HPA develop-
ment varies considerably across mammalian species.
The development of the ΗΡΑ axis in the human fetus
is a complex process involving maturation of fetal organs
as well as interaction with placental and maternal endo-
crine systems [28]. In late pregnancy, a rise in fetal cortisol
levels is necessary to stimulate the development of organ
systems such as the lungs. However, it seems clear that
an excess of fetal glucocorticoids may result in growth
restriction of the fetus as well as influencing the postnatal
adaptation and activity of the pancreas, pituitary-adrenal
axis and cardiovascular activity [29]. Postnatally, an adap-
tive stress response occurs via perceptual cues relating to
threat, disruption of expectancies, physical pain, infection
or metabolic crisis. Such cues are communicated to the
hypothalamus via specific pathways. These signals are
integrated in the hypothalamic paraventricular nucleus,
where neurons expressing corticotropin-releasing hormone,
in collaboration with other peptides such as vasopressin,
stimulate the release of adrenocorticotropic hormone
(ACTH) from the anterior pituitary gland [30]. When
released into circulation, ACTH stimulates the adrenal
cortices to synthesize and release cortisol. The link between
pituitary ACTH and adrenal cortisol appears to be estab-
lished some time after week 20 of gestation [28].
In early gestation, the fetal adrenal cortex produces
small amounts of cortisol that gradually increase during
the third trimester [28]. Across the second trimester,
placental ACTH, in combination with other placental
hormones, regulates fetal production of adrenal ste-
roids. By the third trimester, the fetal pituitary gland
seems to become integrated with the fetal adrenal cor-
tex [28]. By late gestation, the human fetal HPA axis is
well developed and functions as a stress-response system
in response to stressors such as hypoxia or nutrient re-
striction. Therefore, external factors that reduce uterine
vascular flow may initiate a fetal stress response similar to
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HPA activation begins to function according to its
well-known negative feedback mechanism, whereby
mineralocorticoid and glucocorticoid receptors that
are expressed extensively across the hypothalamus and
hippocampus operate to inhibit the stress response
[30]. However, these two receptors play different roles
in modulating both the stress response and the circadian
rhythm. (Detailed reviews of the HPA system and its fetal
development are available in De Kloet et al. [30]).
The fetal stress response is rapidly transformed post-
natally into a circadian rhythm with a peak around the
time of waking and a trough during the day that starts
to operate within a few weeks of birth for a term baby [32].
The normal circadian rhythm can facilitate termination
of the HPA stress response; conversely, disturbances in
the daily rhythm may contribute to HPA stress dysregula-
tion [33]. This postnatal interaction between circadian
rhythm, stress response and sleep patterns illustrates how a
structure-function relationship established in fetal develop-
ment can also come to function as the platform for more
complex developmental systems. Although these have not
been so clearly articulated, similar patterns may exist for
the development of interpersonal, emotional and behavioral
responses across childhood and adolescence [18].
It follows that placental biology has also been closely
linked to the fetal programming of stress response. The
placenta functions as a temporary endocrine structure
that not only regulates the transfer of nutrients to the
fetus but also protects it from the growth-inhibiting ef-
fects of maternal glucocorticoids [34]. The placenta
serves as a critical interface between maternal and fetal
physiology, allowing alterations in maternal endocrine,
metabolic and immune systems across pregnancy to
interact with fetal development. There is an increasing
research focus on the role of the placenta as the link
between maternal prenatal distress and infant out-
comes. Much of this research has focused on an enzyme
(11β-HSD2) that specifically inactivates glucocorticoids,
is highly expressed within the placenta, and has been
suggested to play a role in the ontogeny of the fetal
HPA-axis [34,35]. Placental 11β-HSD2 represents a key
biomarker of the transmission of maternal stress in
pregnancy to the fetus. The placenta may be a central
target of maternal pregnancy stress effects and a key
mechanistic link between maternal functioning and
child mental health outcomes [36].
A number of recent studies are pointing to prenatal
maternal stress and depression being key exposures asso-
ciated with altered epigenetic patterns in both placental
tissue and cord blood. These studies provide evidence
of alterations in epigenetic programming within specific
genes associated with fetal HPA development. Previous
studies have used genome-wide DNA methylation scansto examine exposure to psychotropic medications and
psychiatric illness in both placenta and cord blood [37,38]
and found numerous sites of differential methylation.
Alteration in DNA methylation associated with intrauterine
exposure to depression has been identified in a number
of genes explicitly involved in stress-response systems.
For example, Oberlander et al. found elevated methyla-
tion of the glucocorticoid receptor gene NR3C1 in cord
blood samples from infants born to mothers with de-
pression during the third trimester of pregnancy [39]. In
their study, infant HPA reactivity was assessed at three
months of age using a measure of information processing
designed to induce a mild degree of attention reactivity
and, therefore, cognitive stress. Levels of NR3C1 DNA
methylation in fetal cord blood predicted the infant’s
cortisol response to this mildly stressful task.
Major categories of fetal exposure
The quality of the fetal environment can be compromised
in several ways. The first is an indirect pathway where
physiological reactions to stress such as endocrine, meta-
bolic or immune responses or toxins like nicotine or alco-
hol produce vascular restrictions, thereby impeding oxygen
and nutrition supply to the fetus. The second pathway is a
direct transfer of maternal glucocorticoids or other agents
across the placenta. In the late 1990s, Nathanielsz summa-
rized three main classes of prenatal exposure that have
been investigated for a range of general health outcomes:
lifestyle factors, such as exercise and nutrition; maternal
mental health, covering issues of antenatal stress, anxiety
and depression; and teratogenic and neurotoxic exposures
to specific toxins, such as substance abuse, environmental
toxins and prescribed medications [40]. Each class of
exposure has also been investigated specifically in terms
of child and adolescent mental health outcomes and will
be used as a guide for the review of such exposures.
Lifestyle factors
Lifestyle factors such as exercise and nutrition exert a
clear influence on maternal and fetal health across preg-
nancy and have been central to the investigation of fetal
programming - mostly looking at cardiovascular and
metabolic outcomes. Barker et al. noted effects on fetal
development of maternal diet based on relatively extreme
circumstances such as famine [41]. Maternal diet is critical
to offspring growth rates and also has a programming
effect on metabolic pathways. These mechanisms are
thought to impose lifelong risks for the development of
both diabetes and obesity [42].
However, recent work suggests that maternal diet may
also exert an influence on the biological systems that
underpin future vulnerability to mental disorders [43,44].
Epidemiological evidence suggests that maternal and infant
diet influences the risk for both emotional and behavioral
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ported data from the Mother and Baby study of Norwegian
mothers, showing that a higher intake of unhealthy foods
during pregnancy predicted behavior problems among
children after controlling for a range of confounders. Both
maternal nutrition during pregnancy and lactation could
be an influence [46].
There is also an emerging body of evidence that maternal
obesity during pregnancy is associated with the offspring’s
subsequent mental health outcomes. Rodrigues et al. found
that maternal pre-pregnancy obesity was associated with
child inattention symptoms and emotional difficulties [47].
Van Lieshout et al. conducted a systematic review of stud-
ies on maternal obesity up until 2011 and found that 8 out
of 12 studies showed associations between maternal preg-
nancy obesity and offspring cognitive problems, attention
deficit hyperactivity symptoms, eating disorders in adoles-
cence and psychotic disorders in adulthood [48]. Rodrigues
suggested that while maternal adiposity at the time of con-
ception may have a programming effect for child mental
health, the possible mechanisms remain obscure [47].
Mechanisms for the impact of lifestyle factors can be
considered in terms of maternal mechanisms; placental
mechanisms, where vascular and metabolic pathways
converge in terms of placental function and would expect
to be reflected in intrauterine growth retardation as a com-
mon pathway; and fetal mechanisms, such as epigenetic
changes or differential fetal brain development in response
to blood-borne factors that cross the placenta. Fetal path-
ways would also include fetal counter-regulatory responses
to exposures, such as altered blood glucose or lipid ratios,
and activation of hormonal signaling molecules such as
leptin. While elucidation of the mechanism involved re-
quires further consideration, there are plausible biological
pathways involved and this emerging research strongly
suggests that a range of lifestyle factors operating across
pregnancy appear to influence the child’s subsequent
mental health. The relative effects of nutrition, physical
activity, obesity and other lifestyle factors are complex
and may well interact. However, the evidence appears to
be growing that maternal pregnancy and pre-pregnancy
lifestyle factors do influence fetal development, and as
such would become a modifiable target for prevention
intervention.
Maternal depression and stress during pregnancy
It is well established that children are adversely affected
across multiple domains when their mothers’ perinatal
mental health is untreated or ineffectively treated [49,50].
Several lines of evidence suggest that perinatal exposure to
maternal depression is associated with dysregulation of
the child’s HPA response to stress, increasing risk for
future stress-related disorders. A wide range of negative
child outcomes following maternal depression in thepostnatal period have been well documented and these
include increased waking cortisol levels during adoles-
cence [51], larger amygdala volume and higher cortisol
level at 10 years, higher levels of childhood emotional
problems [52], and higher rates of childhood and ado-
lescent depressive symptoms [53]. Infants of depressed
mothers show more negative affect and lower sensitivity
[54,55] and offspring may experience inadequate physical
and verbal stimulation [56].
The global definition of perinatal depression includes
both prenatal and postnatal maternal depression and there-
fore does not allow a clear differential of the effects derived
from the intrauterine versus postnatal effects. Around 50%
of women with postnatal depressive symptoms have also
experienced depression during their pregnancy [57,58].
It is well established that postnatal depression reduces
the sensitivity of the mother when interacting with her
child and this results in poorer stress regulation and inse-
cure attachments. A meta-analysis of seven studies found
that the infants of depressed mothers also showed signifi-
cantly reduced likelihood of secure attachment and raised
likelihood of avoidant and disorganized attachment [59].
Essentially, the putative mechanism here is the negative
effects of postnatal maternal caregiving in the context of
maternal depression.
However, a fetal programming pathway for the transmis-
sion of maternal prenatal depression to offspring outcome
is also a likely contributor that has been relatively neglected
by developmental researchers. Animal studies have clearly
shown that stress experienced by the mother during preg-
nancy is associated with long-term neurobiological and be-
havioral effects on her offspring [60]. Studies of prenatal
maternal distress in humans show adverse child outcomes,
which include symptoms of ADHD [61], lowered cognitive
performance and delayed language development [62].
Maternal prenatal stress has an impact on her child’s
physiological responsiveness to stress. Specifically, recent
studies have found that maternal life stressors during
pregnancy predict infant cortisol levels and reactive tem-
perament [63-65], and higher resting cortisol throughout
the day in adolescence [66]. It would appear that chil-
dren born to stressed mothers have higher levels of cor-
tisol, which follows from the disruptions to fetal stress
biology previously described. Studies of the relationship
between prenatal stress and child mental health have
been reviewed recently by Glover [67], van den Bergh et al.
[68] and Räikkönen et al. [69], so here we refer to only
a selection of larger studies.
Maternal prenatal stress in various forms is associated
with a number of mental health disorders, but most pre-
vious research has been based on disaster records or
retrospective assessment of prenatal stress. Khashan
et al. [70] used two Danish national registries and found
that maternal prenatal exposure to a family bereavement
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risk of schizophrenia in offspring after adjustment for
demographic confounders. Spauwen et al. [71] reported a
small increase in risk of psychosis in adolescents whose
mothers reported high levels of stress during pregnancy.
Kinney et al. used data from the national weather service
and found that the prevalence of autism spectrum dis-
order increased markedly with the severity of a storm or
hurricane if it was experienced during late pregnancy [72].
Watson et al. [73] found that maternal prenatal exposure
to a severe earthquake in China was associated with an in-
creased risk of depressive symptoms in offspring, and this
risk was more than double for male offspring exposed in
the second trimester as compared to female offspring.
A number of large cohort studies have examined mater-
nal anxiety and depression in pregnancy to prospectively
predict child mental health outcomes. Loomans et al. [74]
examined prenatal state anxiety and child outcomes at five
years of age in a sample of over 3,000 mothers from
the Amsterdam Born Children and their Development
study. Maternal state anxiety measured at 16 weeks’
gestation was significantly associated with an increased
likelihood of inattention or hyperactivity problems for
boys (odds ratio = 2.39) but was not significant for
girls. Using the Avon Longitudinal Study of Parents
and Children, O’Connor et al. [65,75] examined over
7,000 mother-child pairs and found that prenatal ma-
ternal anxiety measured at 32 weeks was a significant
predictor of inattention or hyperactivity symptoms in
boys at 48 and 81 months. However, maternal anxiety
measured at 18 weeks’ gestation was not a significant
predictor of inattention or hyperactivity scores in boys
or girls. Drawing on the Mater University of Queensland
Study of Pregnancy, Clavarino et al. [76] examined a sam-
ple of close to 4,000 mother-child pairs and reported that
high prenatal maternal anxiety was associated with an in-
creased risk for attention problems at 5 years that remitted
by 14 years (odds ratio = 1.45) and with persistent anxiety
problems from 5 to 14 years (odds ratio = 3.02). Robinson
et al. [77] studied a sample of 1,700 drawn from the West
Australian Raine Study. Women were asked at 18 and 34
weeks’ gestation if they had experienced major life stressors
and then completed the Child Behavior Checklist when
their children were two and five years of age. This study
found that a higher number of stressful events was associ-
ated with a 23% increased likelihood of behavioral problems
at age two and five and a 15% increase in the likelihood of
emotional problems at age five.
The bulk of the evidence, and current practice in peri-
natal mental health, is concerned with addressing mater-
nal antenatal depression and anxiety so as to improve the
chances of more effective parenting postnatally. How-
ever, the findings emerging from fetal programming re-
search suggest that child stress biology is probably beingestablished during the intrauterine period and that pre-
ventions should be focused on preconception and preg-
nancy mental health and stress exposure of mothers.
Prenatal teratogenicity and neurodevelopmental toxicity
Prenatal teratogenicity originally referred to the risk of
alteration in fetal development resulting in structural
changes and malformations in offspring from the use of
specific agents in the first trimester of pregnancy. This
concept has been expanded to refer to a broader range
of exposures across pregnancy, and to outcomes beyond
malformations that include longer term child develop-
mental and behavioral outcomes [78]. For an agent to be
considered a teratogen there must be a specific mechan-
ism by which that agent alters fetal development, and
these effects need to occur with particular timing of
exposure during pregnancy and show a dose effect in
relation to the outcome of interest [79]. Recent work in
environmental chemical exposures highlights the need to
consider a broader category of neurodevelopmental tox-
icants. In particular, low-dose exposure to a number of
chemicals with endocrine-disrupting properties is related
to adverse neurodevelopmental outcomes in a non-dose-
dependent manner [80]. This departure from classical
pharmacological models is predicted from the interplay
between a complex and tightly controlled endogenous
biological system and an exogenous chemical with bio-
logical effects outside of normal physiological boundaries.
The elucidation of biological pathways does however re-
main a fundamental step in establishing a convincing case
for causality in observed statistical associations between
exposure and outcome.
Prenatal teratogenic exposures have been widely investi-
gated, and well-documented associations with increased
risk of emotional, behavioral and cognitive problems
include environmental neurotoxicants like lead; substances
of abuse such as alcohol, cigarettes and cocaine; and
prescribed medications, such as the antiepileptic drug
sodium valproate. The evidence for effects from other
psychotropic medications is less well established [21,81-84].
Cigarette smoking has been found in up to 11.8% of
pregnant women [85], with 30.3% of women having
some alcohol in pregnancy but only 2.7% having alco-
hol across all trimesters [86]. Illicit substance use is
likely to be lower, as is exposure to antiepileptic drugs.
However, exposure to antidepressant medications was
found in as many as 13.4% of pregnancies in one study
from Tennessee in the US [87]. Environmental chemical
exposures, by contrast, can be near ubiquitous, underlin-
ing the population significance of even subtle neurodeve-
lopmental toxicity. Consider for example that between
1976 and 1980, 77.8% of the US population had blood
lead levels that were more than double the current
threshold for reporting [88].
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maternal smoking in pregnancy and a range of pregnancy
and child health outcomes, from growth restriction and
preterm delivery to childhood respiratory illness. Increased
incidence of childhood mental illnesses and symptom-
atology, specifically ADHD and conduct problems, have
also been consistently observed [89-93]. Even environ-
mental tobacco exposure (passive smoking) is associated
with adverse behavioral outcomes [94-96], although a
causal biological pathway has not been established. An
association with childhood anxiety and depressive symp-
toms has been observed [97], but not consistently [93]. A
number of recent studies have raised doubts about whether
the observed associations between maternal smoking
during pregnancy and childhood mental health are fully
causal in nature or reflect, in part, shared genetic sus-
ceptibility. In the Avon Longitudinal Study, the effects
size for paternal smoking was of similar magnitude to
that of mothers [98], and in a study of children born fol-
lowing assisted reproduction, the association between
maternal smoking in pregnancy and childhood ADHD
symptoms was greater in those where the child was gen-
etically related to the mother [99]. Shared inheritance
does not, however, appear to account for all of the ob-
served association between ADHD and prenatal tobacco
exposure in other cohorts [91,93,100]; a recent study
from Taiwan explicitly tested and found evidence for a
biological pathway that is dependent upon tobacco-related
chemicals. Hsieh et al. used genetic studies of children
to demonstrate that the association between cord blood
cotinine and childhood behavioral difficulties is modified
by a genetic polymorphism in the metabolic pathway for
smoking-related toxicants [94].
Alcohol has also been associated with a range of terato-
genic effects, from fetal alcohol syndrome to a broader fetal
alcohol spectrum and later onset developmental and behav-
ioral problems, such as low IQ, specific learning disorders,
and internalizing and externalizing symptoms [101,102]. Of
the other drugs of abuse, cocaine [103,104], marijuana, ben-
zodiazepines and methamphetamine [105] have each been
associated with effects on neurodevelopment and later child
mental health outcomes that appear to be independent of
social factors [106,107]. These effects are subtler than earl-
ier research in the area, and are not apparent until much
later in child development and therefore referred as latent
or ‘sleeper’ teratogenic effects [78]. The evidence for opiate
exposure is unclear [103]. Epidemiological research in the
area is complicated by covariance between substance use
and social factors and, in the case of opiates, the small
numbers of pregnancies affected and challenges of follow-
up in this relatively chaotic social group.
More recently, longitudinal studies have started to focus
on psychotropic medications including antidepressants,
antipsychotics and mood stabilizers. Studies from NorthAmerica have shown an increasing rate of antidepressant
exposure in pregnancy, ranging from 7.6% to 13.4% in the
US and 5% in Canada [87,108,109]. In Australia, the rate
has been shown in data from the Longitudinal Study of
Australian Children to be around 2.1% [110]. The diffi-
culty in examining these agents for potential teratogenic
effects is untangling the potential impact of the often ser-
ious maternal mental illnesses these agents are used to
treat as well as co-morbid exposures that confound out-
comes. For instance, one study examining malformation
risk and antidepressant exposure found fetal alcohol
syndrome was 10 times more likely in children exposed
to antidepressants in pregnancy [111].
The most rigorously studied psychotropic class is the
antiepileptic drugs, which, in addition to being used in
epilepsy, are used as mood stabilizers for treatment of
bipolar disorder. These agents have previously been as-
sociated with an increased risk of specific structural
teratogenicity, such as an increased risk of neural tube
defects. There are now a number of rigorous, prospective,
longitudinal studies that have followed children from preg-
nancy to school age to examine for neurodevelopmental
and behavioral teratogenic effects [112]. They have identi-
fied specific risks with exposure to specific agents and a
dose effect. The antipsychotic medications, both typical
and atypical, are not associated with a malformation risk
but the literature for longer term effects is far too lim-
ited to draw any conclusions about child development
outcomes [113,114].
There are now a number of large studies of anti-
depressant exposure in pregnancy and malformation
risk but there is still no consensus as to whether there
is a small increased risk of birth defects [115]. Studies
of longer term teratogenic risks are more limited and
most have a small number of participants and short
follow-up [116]. However, while no studies to date
have found an effect of exposure on global cognition,
there are four studies that have found an increased risk
of poorer motor development [117-120]. It is import-
ant to balance these findings with a number of studies
that have found that untreated depression is associated
with poorer development, particularly language devel-
opment [121]. Given the increasing rate of exposure to
this class of psychotropic medication, further studies
are required that can robustly quantify the potential
risks of exposure to balance against the harms of with-
holding treatments. Such studies ideally require longer
follow-up, robust consideration of maternal depression
and other confounding factors, and more robust child
development measures in order to reach clear conclu-
sions [87,108,122,123].
It can be concluded from studies on psychotropic
medication that, to minimize effects on longer term
child development, single agents should be considered
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keeping doses as low as is feasible for effective treat-
ment. There is an urgent need for further studies to
delineate risks for specific agents so that more informed
choices can be made [124-126]. When considering the use,
and hence exposure, to antidepressants in pregnancy, the
issues relevant to child development and mental health out-
comes are not just those that relate to exposure per se but
also to the impact of untreated maternal mental illness.
There is mortality data in both the UK and Australia that
suggest mental illness is a leading indirect cause of maternal
deaths [127]. In addition, untreated depression poten-
tially impacts on the capacity of women to self-care in
pregnancy, particularly in important areas that are in-
creasingly associated with optimal fetal growth and
development, such as nutrition and exercise. Finally,
clinicians and patients need to consider the effects that
remaining depressed may have on a woman’s capacity to
enjoy motherhood, bond with her baby, and provide re-
sponsive and sensitive parenting to the child. All of these
aspects of parenting also have a significant impact on
short- and long-term child outcomes.
Environmental teratogens and neurodevelopmental
toxicants differ from the above by the locus of control of
the mother with respect to exposure, but are neverthe-
less an important modifiable risk factor for preventative
mental health strategies. Lead exposure is the prototypic
environmental neurotoxicant. Historical exposure was
through use of lead in water pipes carrying drinking
water, as a fuel additive, and in paints and certain toys.
Lead persists in the environment and current household
exposure is understood to be primarily from historical
soil contamination and old paint, although lead does
also continue to be used in a restricted form in hobby ac-
tivities including soldering, pottery, collectables such as toy
soldiers, certain artists’ paints, ammunition and fishing
sinkers. Large longitudinal studies demonstrate that pre-
natal [128-130], lifetime [129,131] and current exposure
[132-134] are each important [135-137] for neurodeve-
lopmental outcomes. The proposed biological mecha-
nisms have supportive in vitro evidence, including
inhibition of N-methyl-D-aspartic acid glutamate recep-
tors (the key molecule regulating synaptic long-term po-
tentiation) and interaction with calcium ion signaling,
with much wider implications. Although much research
has focused upon outcomes of general cognitive ability
and/or ADHD, there is well-replicated evidence for an
association between lead exposure and adverse outcomes
across broad ranging neurodevelopmental outcomes, in-
cluding both behavioral and emotional symptomatology
[138-141]. The effect size is substantial. Froehlich et al.
estimate that in the US, 25.4% of ADHD in 8- to 15-
year-olds is attributable to the low levels of exposure
that persist today [142]. Their analysis used data from theUS National Health and Nutrition Examination Survey
(NHANES) study, a cross-sectional study but whose design
facilitates it having the statistical power to look at clinical
outcomes rather than symptomatology.
The evidence base for lead exposure and neurodevelop-
mental outcomes is not matched anywhere else in the
environmental chemical literature. Other environmental
chemicals with established neurodevelopmental toxicity
include methyl mercury and the polychlorinated biphenyls
(PCBs). Environmental exposure to each has established
associations with general cognitive function, although
the relevance to broader mental health is less clear
[143]. Interestingly, the longitudinal data that does exist
support an association with prenatal but not postnatal
exposure, in support of the DOHaD hypothesis [143].
The strongest evidence is for associations with ADHD
and executive function deficits [143]. Wider mental health
outcomes have not been adequately studied to draw con-
clusions, although data would exist in the New Bedford
cohort [144,145] that we have not been able to find in pub-
lication. Biological mechanisms are also unclear, although
PCBs are potent endocrine disruptors and modeling sup-
ports thyroid function as a putative mechanism [146].
No consistent specific pattern of deficits emerges that
distinguishes neurodevelopmental toxicity due to lead
from that due to mercury or PCBs. Observed outcomes
in each span both cognitive and affective domains [143],
suggesting common developmental pathways of neuro-
developmental toxicity with relevance to mental health.
Research to date does imply that cognitive performance
and behavioral problems are more strongly associated
with environmental toxicity than emotional problems,
although it is not clear if this is due to greater sensitivity
to neurodevelopmental toxicity, or greater sensitivity in
the population-based methodology and assessment tools
used to detect subtle effects at the population level.
Exposure to lead and PCBs are on the decline, and
methyl mercury exposure appears to be stable [147-150].
Yet there is substantial work still to be done to further
reduce exposure to these established neurotoxicants,
most notably lead, where the ongoing effects of expos-
ure estimated from the US NHANES data mean that
this must remain a key priority in the preventive mental
health agenda [142]. At the same time there is a growing
body of modern chemicals - not previously evaluated
for neurodevelopmental toxicity - that now raise concern
as potential neurotoxins in need of further evaluation
[143,151]. These include manganese and cadmium -
bivalent heavy metal cations like lead and mercury -
and many chemicals with endocrine-disrupting actions
in vitro similar to those of PCBs (for example, bisphenol
A, phthalates, organochloride pesticides, organophosphate
pesticides, brominated flame retardants and perfluorinated
compounds). The robust evaluation of these chemicals is
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health. However, beyond even this, there is an appreciation
that the potential for neurodevelopmental toxicity is un-
known for the vast majority of chemicals in ubiquitous
modern usage [151], emphasizing that there may be other
substantial opportunities for mental health prevention, and
that there is a need to prioritize understanding in this area.
Addressing environmental toxins, smoking, alcohol and
illicit substance use in pregnancy are important to reduce
the implications for child development and mental health
outcomes. The latter three also have implications for preg-
nancy self-care and nutrition. However, there is evidence
that both smoking [152] and alcohol use [111] in pregnancy
are associated with depression in pregnancy. Therefore,
interventions that address a broader approach to a healthy
pregnancy may be warranted.
Positive effects of intrauterine exposures
Whereas most studies focus on negative child develop-
mental outcomes following maternal stress or depres-
sion over pregnancy, a number of studies present some
positive effects of either stress exposure or prescription
of antidepressants. These findings suggest that exposures
during pregnancy are complex and need to be carefully
considered in terms of the type of exposure, its timing,
and potential genetic moderators on child development
outcomes where some children may manifest poor out-
comes while others may in fact benefit from similar
levels of exposure.
For instance, DiPietro et al. reported that increased levels
of particularly anxiety and stress - but not depressive symp-
toms - in pregnancy were associated with higher levels of
motor development and mental development in children at
two years after adjustments for postnatal confounds [153].
Notably the sample consisted of only healthy women with
low-risk pregnancies whose levels of anxiety and depression
were not in the clinical range and stressors were minimal.
Genetic factors also add to the complexity, with some
polymorphisms such as those within SLC6A4 conferring
sensitivity to advanced development within positive en-
vironments [154]. There is also some evidence that the
time of stress exposure within pregnancy may be an im-
portant factor in the outcome. By sampling repeatedly
across pregnancy, Davis and Sandman showed that ex-
posure to higher levels of cortisol in early pregnancy
predicted poorer child development outcomes, whereas
higher levels of maternal cortisol in late pregnancy pre-
dicted accelerated cognitive development [155]. Such find-
ings suggest that effects of mild stress exposure, possibly
towards the later period of gestation, may well confer de-
velopmental advantage.
There are now also limited animal and human studies
that have shown a beneficial effect on offspring exposed
to selective serotonin reuptake inhibitors during earlydevelopment. One study of rats showed fluoxetine expos-
ure protected rat offspring from the effects of pregnancy
stress on adolescent outcomes for both depressive
symptoms, as measured by the Forced Swim Test, and
increased hippocampal neurogenesis [156]. A second
study showed that fluoxetine exposure in rat pups sepa-
rated from their mothers protected against cell apoptosis of
the dentate gyrus of the hippocampus [157]. A study of hu-
man neonates showed early speech perception was more
advanced in those exposed to selective serotonin reuptake
inhibitors than those exposed to controls [158]. Other stud-
ies examining global cognitive development in relation to
antidepressant exposure and maternal depression have also
found a significant effect of maternal depression but not
antidepressant exposure on outcomes [159,160]. Given the
limited number of studies, these findings must be inter-
preted with caution but do build a more complex picture
of the potential risks and potentially protective aspects of
exposure, which also requires consideration of the context
in which the exposure to antidepressants occurs.
Findings of positive effects of certain exposure may at
first appear confusing or suggest methodological flaws in
research. However, some degree of stress is a normal part
of life, and increasing levels of glucocorticoids across preg-
nancy are a normal part of development, serving important
maturational functions for the fetus. Given that clinical
levels of stress and psychiatric disorders impact on multiple
regulatory functions in pregnant women, we can infer
that only relatively mild stressors in late pregnancy would
be advantageous but further research should investigate
this assumption.
Implications for mental health prevention
There is growing evidence from human studies showing
that early exposures to lifestyle factors and maternal
mental health are predictive of child behavioral, emotional
and learning outcomes. Such exposures appear to alter the
developmental trajectory according to subtle programming
effects. These effects may impact, for example, on the
development of the endocrine response to stress, which
can manifest as psychiatric disorder at later points in
development, particularly when a child or adolescent is
confronted by new challenges. This literature on mental
health and lifestyle factors supplements and in many re-
spects expands upon the teratogenic and neurotoxic
models of exposure. These exposures have a deleterious
impact because they introduce intrauterine conditions
which fall outside of biological norms while factors such
as maternal stressors or nutrition probably have their
impact through inducing different trajectories for develop-
ment as the fetus attempts to adapt to variation within the
intrauterine environment. Factors such as illicit sub-
stance exposure, smoking and environmental toxins also
have strong evidence of associations with child mental
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tute important areas for prevention efforts to target.
Such evidence is now sufficiently compelling that it
calls upon researchers to translate such findings into
interventions designed to prevent mental disorders. The
need for prevention is particularly acute given that mental
health treatment systems are coping poorly with demand
for mental health services and typically service around
20% of the population’s clinical need [161]. Prevention sci-
ence and practice has a vital but somewhat neglected role
to play in transforming health, education and community
service systems to enable the developmental causes of
major sources of mental disorder to be effectively targeted.
Population and public health models are increasingly
being considered as a vehicle for the prevention of high
prevalence mental health disorders in childhood, with
a focus on attention, emotional and behavioral disor-
ders. It is becoming clearer that risk factors for such
common disorders show considerable cross-over with
risk factors for major non-communicable diseases [162].
Optimizing health cannot be detached from optimizing
mental health [163].
Already a number of successful programs have been
developed, such as nurse visitation in the perinatal
period [164]. The Nurse-Family Partnership program,
originally trialed in New York, has now been replicated
in several different populations and shows ongoing child
development benefits up to nine years of age [165]. This
program comprises home visits by nurses for first-time,
disadvantaged mothers across pregnancy and early in-
fancy. The program has three aims: first, to improve
pregnancy health and outcomes; second, to improve child
health and development; and third, to help parents plan
future pregnancies, complete their education and find
work [166]. The Nurse-Family Partnership program is as-
sociated with a wide range of beneficial outcomes, but of
interest to this review is the significant effect on child out-
comes, including educational improvement, as compared
to control children [165].
A recent Cochrane review reported emerging evidence
to show that current interventions aiming to prevent
postnatal depression in women are of benefit [167]. Not-
ably, few of these interventions also examine outcomes
for children. There is considerable scope for the devel-
opment of effective interventions for pregnant women to
address not only depression but equally anxiety disorders
and high stress exposures [168,169]. Overall, the quality of
evidence for existing prevention programs in the precon-
ception, pregnancy and early infancy period is limited, and
often target only one of the many deleterious factors that
impact on child development.
The ultimate goal of prevention in a mental health
context refers to measurably reducing the population
rates of mental health disorders by using strategic effortsto address their known causes. Since it often adopts a
population perspective, prevention science tends to remain
at some distance from research on the neurobiological
systems implicated in early development. However, pre-
vention efforts could effectively target immature, develop-
ing neurobiological systems. Early experience research is
highly applicable to prevention as it suggests ways that
not only adverse postnatal experiences but also precon-
ception and intrauterine factors might constitute targets
for prevention efforts.
The current review has identified strong evidence for
the deleterious impact of maternal mental health and a
range of teratogenic and neurotoxic factors. There is also
emerging evidence for lifestyle factors such as diet and
obesity. Further robust evaluation of psychological and
chemical exposures that cross the placenta or impede
placental function via compromised maternal health
and mental health will continue to create substantial
new opportunities in preventative mental health. The
general implication of the DOHaD model is that the
prevention of compromised fetal development would
potentially have long-term health and mental health
benefits for offspring.
We have focused on three major classes of pregnancy
exposure - not to suggest that these are exhaustive but to
provide a framework to guide consideration of intervention
efforts. As Schlotz et al. note, an interesting feature of the
fetal programming research is that the diverse range of
exposures reviewed - such as prenatal smoking, stressful
events and depression - show broadly speaking similar
patterns of outcomes in terms of child behavioral, emo-
tional and attention deficits [21]. This suggests placental
transmission or compromised placental function may
comprise a small number of mechanisms that interrupt
fetal development and therefore result in a similar set of
child outcomes. It also shows the commonality between
mental health and other health outcomes. Fetal growth,
therefore, could continue to be considered a useful index
of fetal adversity but also as an outcome for prenatal and
preconception intervention to target, particularly for
population-level interventions.
Pregnancy care provides a convenient opportunity for
health interventions given the high level of engagement
with the health delivery system, and this is a key time point
to target public health strategies around psychological and
physical preparation for pregnancy, smoking, alcohol, diet,
and exposure to known teratogen and neurodevelopmental
toxins. However, given that 40% or more of pregnancies are
unplanned, and given the importance of the preconception
period for many factors we have identified here, a broader
approach is needed. Effective strategies would therefore
be anticipated to combine targeted interventions within
pregnancy care, with broader interventions that will reach
all women of child-bearing age, or that are effectively
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supplementation for prevention of neural tube defects.
This is especially relevant for developing strategies to-
wards reducing environmental exposure to chemicals
with neurodevelopmental toxicity.
Interventions that recognize and support the formation
of a family unit are important to consider as an alternative
to focusing intervention only on maternal care. Partner
support has consistently been found to be a major pre-
dictor of maternal coping with stress and perinatal depres-
sion. Policies and practices to support pregnant women in
the general population and also efforts to support women
at elevated risk are of particular importance. In perinatal
psychiatry, the development of antidepressants that do
not cross the placenta and therefore do not impact on
fetal development are currently in the development phase
and, if effective, t could have a significant impact on redu-
cing antenatal maternal depression and anxiety.
Recommendations arising from the current review are
threefold. First, to develop recommendations on pregnancy
health based on the current evidence base on exposures
relevant to optimizing the mental health of offspring. Such
recommendations need to be examined in relation to other
preventative measures aimed at improving general preg-
nancy health so as to capitalize on the commonality of
risk factors for both child health and mental health out-
comes. Second, health promotion programs targeted to
both the public and health professionals to encourage
full implementation of such recommendations. Third, tar-
geted intervention to high-risk groups, which might take
the form of behavior and education programs for young
adult women of child-bearing age in high risk groups
concerning pregnancy health and infant development.
High risk groups include women who in preconception
or during pregnancy experiencing major (mental) health
difficulties or other disadvantages, major stressors or other
adversities, and mothers of infants who are premature,
of multiple birth, or have birth complications, low birth
weight or failure to thrive.
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